Feb 22, 2024 7:00am EST Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Feb 21, 2024 7:00am EST Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Jan 05, 2024 7:00am EST Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Nov 07, 2023 7:00am EST Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 01, 2023 4:01pm EDT Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
Oct 21, 2023 8:45am EDT Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial